Sign in →

Test Code C199 Carbohydrate Antigen 19-9 (CA 19-9)

Specimen Type



Mint green top with gel separator

Preferred Volume

3.5 mL

UCMC Collection Instructions

 Once per admit. If serial monitoring needed, Q daily.


Monday – Friday 7:00 a.m. – 6:00 p.m.

Turnaround Time

24 – 72 hrs

STAT Availability

Not Available

Test Usage

Immunoassay for the in vitro quantitative determination of CA 19-9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19-9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.

Test Methodology

Roche Elecsys CA 19-9, Electrochemiluminescence Immunoassay (ECL)

Additional Information

The measured CA 19-9 value of a patient’s sample can vary depending on the testing procedure used.  CA 19-9 values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.
Patients known to be genotypically negative for Lewis blood group antigens will be unable to produce the CA 19-9 antigen even in the presence of malignant tissue. Phenotyping for the presence of the Lewis blood group antigen may be insufficient to detect true Lewis antigen negative individuals. Even patients who are genotype positive for the Lewis antigen may produce varying levels of CA 19-9 as the result of gene dosage effect.

CPT Code


Test Includes

CA 19-9

Critical Results


Reference Range

< 37 U/mL

Coverage Information

CMS has established a national coverage policy (NCD) for Medicare for this test as of November 25, 2002. Please document medical necessity. For more details click this link:



Minimum Volume

2 mL

Fee Code



CA 19-9